Action
Glutamate blocker, AMPA receptor antagonist

Status
Phase I studies showed YM872 was well tolerated at 1.25 mg/kg/h when given as a 24-hour infusion to healthy subjects. Elderly subjects had euphoria or sedation at higher dose levels. Phase II trial ongoing.

Trial(s)
  = Ongoing
  = Completed

	ARTIST +	AMPA Receptor Antagonist Treatment in Ischemic Stroke Trial
	ARTIST MRI	AMPA Receptor Antagonist Treatment in Ischemic Stroke

UID: 56